Status: Recruiting
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
Participants needed: 402
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SK Bioscience Co., Ltd.Updated: Dec 23, 2025Locations: 3
Eligibility criteria
For Stage 1, participant must be 18 to 55 years of age inclusive, at the time of... [+6]
Any clinically significant respiratory symptoms (e.g., cough, sore throat), febr... [+18]